Wednesday, October 12, 2016 5:13:33 PM
There are certain situations that INVO does not fit as a solution. That is why there have been criteria for the INVOcell trials so it is obvious that INVOcell will not work for 100% of the infertility cases out there, so will it replace IVF completely? short answer...NO.
Besides, traditional IVF labs did not spend all that money just to throw away their investment and switch to INVOcell.
INVOcell was never meant, I don't believe, to take over the IVF industry. Rather, it was seen as providing an option for those who could not afford traditional IVF and thereby make fertility an option for those who could not afford the full cost. So it wasn't seen as replacing but rather opening up a market that could not otherwise afford IVF. However, if couples opt for a lower cost option, all the better.
Now the proof of this is that traditional full service IVF clinics are signing up for that very reason. If INVOcell was meant to completely takeover you wouldn't see this occurring. INVOcell provides an additional revenue stream since these customers would not have moved forward without this lower-cost option. So why not come on board? Makes perfect sense.
So the full IVF clinics add it as a lower cost option and then there is of course TCART in Canada which made it an additional cost option for those seeking the "natural" experience. Seems like a dumb thing to do but maybe the people that go there already have a connection with this clinic and don't have a problem paying more for this option. It's a one-off clinic, no big deal. Think of it like those customers who would buy Sony just for the name, go figure.
Maybe they rethink that strategy when the INVO-only clinics start to rollout. Of course I'm referring to the first partnership with Effortless IVF in Canada. They are doing INVOcell only (which again does not address 100% of infertility cases). This group led by Jason Broome have been involved with INVOcell for a looooong time and have made a strategic investment in its success. They have now said that they plan up to 12 clinics over time which is great news for INVO Bio.
I doubt that Effortless IVF will be the only clinics to rollout in this manner. There will be others where IVF is a geographic challenge. The ability to open a clinic with a much lower investment is a perfect option for obgyn's or those looking to repeat the Effortless IVF model.
Anyway, all this is to agree that while INVOcell can carve a significant chunk of the IVF market, it certainly wont replace ALL of the traditional IVF market.
Recent INVO News
- Micro Cap Massively Bid Up Before Opening Bell • AllPennyStocks.com • 04/17/2024 02:25:00 PM
- INVO Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/16/2024 08:59:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:24:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:01:07 PM
- NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 01/16/2024 10:29:59 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/10/2024 09:46:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:05:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:29:45 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 12/28/2023 10:04:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 10:02:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/13/2023 10:08:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:53:21 PM
- NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal • PR Newswire (US) • 12/11/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 10:18:38 PM
- INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • PR Newswire (US) • 11/28/2023 02:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/24/2023 06:08:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:59:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:10:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:06:04 PM
- INVO Reports Record Third Quarter 2023 Financial Results • PR Newswire (US) • 11/13/2023 09:01:00 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 11/13/2023 02:23:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:21:54 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/13/2023 02:12:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM